N Mansour1,2, C Backes3, C Becker4, B Hofauer4,3, A Knopf4,3. 1. Klinik für Hals, Nasen- und Ohrenheilkunde, Universitätsklinikum Freiburg, Killianstr. 5, 79106, Freiburg, Deutschland. naglaa.mansour@uniklinik-freiburg.de. 2. Klinik und Poliklinik für Hals‑, Nasen- und Ohrenheilkunde, Klinikum rechts der Isar, Technische Universität München, München, Deutschland. naglaa.mansour@uniklinik-freiburg.de. 3. Klinik und Poliklinik für Hals‑, Nasen- und Ohrenheilkunde, Klinikum rechts der Isar, Technische Universität München, München, Deutschland. 4. Klinik für Hals, Nasen- und Ohrenheilkunde, Universitätsklinikum Freiburg, Killianstr. 5, 79106, Freiburg, Deutschland.
Abstract
BACKGROUND: Resection margins in patients with oropharyngeal squamous cell carcinoma (OPSCC) are a predictive marker for overall survival (OS) and recurrence-free interval (RFI). Adjuvant therapy is influenced by TNM status, extracapsular extension (ECE), and resection margin status (R) of the primary tumor. The R status can be directly influenced by the head and neck surgeon. The aim of the current study was to evaluate the impact of R status on treatment decisions, RFI, and OS. MATERIALS AND METHODS: All patients with OPSCC who underwent surgery (with/without adjuvant therapy) between 2001 and 2011 were enrolled. Clinical data, survival parameters, histologic data such as ECE, resection margin status, and tumor size were retrospectively collected and analyzed. RESULTS: A total of 208 patients were enrolled. Survival parameters showed that patients with microscopically clear (R0) resection margins had an RFI/OS of 89/87 months. These values decreased in patients with R1 (65/65 months), R2 (38/33 months), and Rx (unclear) resections (59/45 months; p = 0.036/p = 0.001). In patients with ECE and R1 resection, but also in those with R0 resections achieved by follow-up resection and those with Rx resections, adjuvant therapy was escalated. CONCLUSION: Unclear resection status reduces OS and RFI in patients with OPSCC. Therefore, in surgical therapy, clear resection status in the first pass should be strived for to avoid escalation of adjuvant therapy due to an unclear R status.
BACKGROUND: Resection margins in patients with oropharyngeal squamous cell carcinoma (OPSCC) are a predictive marker for overall survival (OS) and recurrence-free interval (RFI). Adjuvant therapy is influenced by TNM status, extracapsular extension (ECE), and resection margin status (R) of the primary tumor. The R status can be directly influenced by the head and neck surgeon. The aim of the current study was to evaluate the impact of R status on treatment decisions, RFI, and OS. MATERIALS AND METHODS: All patients with OPSCC who underwent surgery (with/without adjuvant therapy) between 2001 and 2011 were enrolled. Clinical data, survival parameters, histologic data such as ECE, resection margin status, and tumor size were retrospectively collected and analyzed. RESULTS: A total of 208 patients were enrolled. Survival parameters showed that patients with microscopically clear (R0) resection margins had an RFI/OS of 89/87 months. These values decreased in patients with R1 (65/65 months), R2 (38/33 months), and Rx (unclear) resections (59/45 months; p = 0.036/p = 0.001). In patients with ECE and R1 resection, but also in those with R0 resections achieved by follow-up resection and those with Rx resections, adjuvant therapy was escalated. CONCLUSION: Unclear resection status reduces OS and RFI in patients with OPSCC. Therefore, in surgical therapy, clear resection status in the first pass should be strived for to avoid escalation of adjuvant therapy due to an unclear R status.
Entities:
Keywords:
Adjuvant chemoradiotherapy; Head and neck neoplasms; Margins of excision; Survival analysis; Treatment outcome
Authors: K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison Journal: N Engl J Med Date: 2010-06-07 Impact factor: 91.245
Authors: Jacques Bernier; Christian Domenge; Mahmut Ozsahin; Katarzyna Matuszewska; Jean-Louis Lefèbvre; Richard H Greiner; Jordi Giralt; Philippe Maingon; Frédéric Rolland; Michel Bolla; Francesco Cognetti; Jean Bourhis; Anne Kirkpatrick; Martine van Glabbeke Journal: N Engl J Med Date: 2004-05-06 Impact factor: 91.245
Authors: Angela T T Wong; Stephen Y Lai; G Brandon Gunn; Beth M Beadle; Clifton D Fuller; Martha P Barrow; Theresa M Hofstede; Mark S Chambers; Erich M Sturgis; Abdallah Sherif Radwan Mohamed; Jan S Lewin; Katherine A Hutcheson Journal: Oral Oncol Date: 2017-01-21 Impact factor: 5.337
Authors: Jacques Bernier; Jay S Cooper; T F Pajak; M van Glabbeke; J Bourhis; Arlene Forastiere; Esat Mahmut Ozsahin; John R Jacobs; J Jassem; Kie-Kian Ang; J L Lefèbvre Journal: Head Neck Date: 2005-10 Impact factor: 3.147
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Anil K Chaturvedi; William F Anderson; Joannie Lortet-Tieulent; Maria Paula Curado; Jacques Ferlay; Silvia Franceschi; Philip S Rosenberg; Freddie Bray; Maura L Gillison Journal: J Clin Oncol Date: 2013-11-18 Impact factor: 44.544
Authors: Salman A Eraj; Mona K Jomaa; Crosby D Rock; Abdallah S R Mohamed; Blaine D Smith; Joshua B Smith; Theodora Browne; Luke C Cooksey; Bowman Williams; Brandi Temple; Kathryn E Preston; Jeremy M Aymard; Neil D Gross; Randal S Weber; Amy C Hessel; Renata Ferrarotto; Jack Phan; Erich M Sturgis; Ehab Y Hanna; Steven J Frank; William H Morrison; Ryan P Goepfert; Stephen Y Lai; David I Rosenthal; Tito R Mendoza; Charles S Cleeland; Kate A Hutcheson; Clifton D Fuller; Adam S Garden; G Brandon Gunn Journal: Radiat Oncol Date: 2017-09-09 Impact factor: 3.481